206 related articles for article (PubMed ID: 11293899)
1. Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions.
Davidson B; Goldberg I; Berner A; Nesland JM; Givant-Horwitz V; Bryne M; Risberg B; Kristensen GB; Tropé CG; Kopolovic J; Reich R
Am J Clin Pathol; 2001 Apr; 115(4):517-24. PubMed ID: 11293899
[TBL] [Abstract][Full Text] [Related]
2. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.
Kitagawa Y; Kunimi K; Ito H; Sato H; Uchibayashi T; Okada Y; Seiki M; Namiki M
J Urol; 1998 Oct; 160(4):1540-5. PubMed ID: 9751409
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
4. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.
Nakada M; Nakamura H; Ikeda E; Fujimoto N; Yamashita J; Sato H; Seiki M; Okada Y
Am J Pathol; 1999 Feb; 154(2):417-28. PubMed ID: 10027400
[TBL] [Abstract][Full Text] [Related]
5. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
[TBL] [Abstract][Full Text] [Related]
7. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
[TBL] [Abstract][Full Text] [Related]
8. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.
Pap T; Shigeyama Y; Kuchen S; Fernihough JK; Simmen B; Gay RE; Billingham M; Gay S
Arthritis Rheum; 2000 Jun; 43(6):1226-32. PubMed ID: 10857781
[TBL] [Abstract][Full Text] [Related]
9. Expression and localization of matrix metalloproteinases (MT1-MMP, MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) during synepitheliochorial placentation of goats (Capra hircus).
Uekita T; Yamanouchi K; Sato H; Tojo H; Seiki M; Tachi C
Placenta; 2004 Nov; 25(10):810-9. PubMed ID: 15451196
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Clin Cancer Res; 2000 Jul; 6(7):2726-34. PubMed ID: 10914717
[TBL] [Abstract][Full Text] [Related]
11. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material.
Haupt LM; Irving RE; Weinstein SR; Irving MG; Griffiths LR
Mol Cell Probes; 2008 Apr; 22(2):83-9. PubMed ID: 17669621
[TBL] [Abstract][Full Text] [Related]
14. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
[TBL] [Abstract][Full Text] [Related]
15. Coordinate expression of membrane type-matrix metalloproteinases-2 and 3 (MT2-MMP and MT3-MMP) and matrix metalloproteinase-2 (MMP-2) in primary and metastatic melanoma cells.
Ohnishi Y; Tajima S; Ishibashi A
Eur J Dermatol; 2001; 11(5):420-3. PubMed ID: 11525948
[TBL] [Abstract][Full Text] [Related]
16. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor.
Nabeshima K; Inoue T; Shimao Y; Okada Y; Itoh Y; Seiki M; Koono M
Cancer Res; 2000 Jul; 60(13):3364-9. PubMed ID: 10910039
[TBL] [Abstract][Full Text] [Related]
17. [Interactions of ovarian carcinoma cells and human peritoneal mesothelial cells involved in matrix metalloproteinases expressions of ovarian carcinoma cells].
Zhang JJ; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2006 Mar; 41(3):194-7. PubMed ID: 16640888
[TBL] [Abstract][Full Text] [Related]
18. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
19. Activation ratio of MMP-2 and expression of MT1-MMP are correlated in thymic epithelial tumours.
Wang Y; Xu HT; Ueda Y; Shimasaki M; Wang EH
Pathology; 2007 Oct; 39(5):486-90. PubMed ID: 17886098
[TBL] [Abstract][Full Text] [Related]
20. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
